SS
ASBP

SBI Securities’s Aspire Biopharma ASBP Stock Holding History

SBI Securities’s Portfolio ASBP Stock Details ASBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11 Buy
+2
New +$20 ﹤0.01% 3923
2026
Q1 		– Hold
0
– – – 4006

Other funds holding ASBP

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CA
Crewe Advisors Salt Lake City, Utah $1.38B AUM 41.76% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
VWM
Valley Wealth Managers Paramus, New Jersey $1.73B AUM 42.12% 1-Year Est. Return
CA
Crossingbridge Advisors Pleasantville, New York $567M AUM 0.34% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

SBI Securities's ASBP Position: Q2 2026 in Review

SBI Securities opened a new position in Aspire Biopharma (ASBP) in Q2 2026: 2 shares worth $11. The stake represents ﹤0.01% of the portfolio and ranks #3923 among its holdings.

13 funds tracked by Wall St. Rank hold ASBP as of Q2 2026.

  • SBI Securities held 2 shares of Aspire Biopharma worth $11 as of Q2 2026.
  • Aspire Biopharma was a new SBI Securities position in Q2 2026.
  • Aspire Biopharma made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3923 holding.
  • 13 funds tracked by Wall St. Rank held Aspire Biopharma as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.